Alemtuzumab- a type of drug known as a monoclonal antibody - was created at Cambridge in the late 1970s, and has long been used to treat leukaemia by killing off the cancerous white cells of the immune system. Also it can be a serious weapon against the multiple sclerosis(MS). But it only in early stage of research. So it can produce potentially serious side-effects as well.
The latest three-year study, of 334 patients with relapsing-remitting MS which had yet to be treated, found that the drug cut the number of attacks of disease by 74% more than the reduction achieved by conventional interferon-beta therapy. It also reduced the risk of sustained accumulation of disability by 71% compared to beta-interferon.
MS is caused by fault in the body's immune system which leads it to attack nerve fibres and their protective insulation.This damage prevents the nerves from 'firing' properly, and then leads to their destruction, resulting in physical and intellectual disabilities.
The latest three-year study, of 334 patients with relapsing-remitting MS which had yet to be treated, found that the drug cut the number of attacks of disease by 74% more than the reduction achieved by conventional interferon-beta therapy. It also reduced the risk of sustained accumulation of disability by 71% compared to beta-interferon.
MS is caused by fault in the body's immune system which leads it to attack nerve fibres and their protective insulation.This damage prevents the nerves from 'firing' properly, and then leads to their destruction, resulting in physical and intellectual disabilities.
Hiç yorum yok:
Yorum Gönder